Shots:

• The study involves assessing of LIQ861 in 109 patients divided in two groups of 65 prostacyclin-naive patients that were stable on ≤2 approved oral PAH therapies and 44 patients transitioning from Tyvaso (transition) with pAH
• The study resulted in median MLWHFQ score @transition and add on patients from 37 to 29 and 30 to 19- median 6MWD 395m and 408m and 428m and 449m- no serious adverse events (SAEs) related to LIQ861- safe and well-tolerated- Presented at 39th International Society for Heart & Lung Transplantation (ISHLT)
• LIQ861 is a inhaled dry powder formulation of treprostinil developed using Liquidia’s PRINT technology targeted as an alternative to current inhaled treprostinil therapy for the treatment of PAH

Ref: Liquidia | Image: Twitter